Flatiron Health has introduced its first global Panoramic datasets for prostate cancer, expanding into the UK and Germany and creating what it calls a unified gold standard for real-world oncology evidence across three major markets.
Prostate cancer affects nearly 1.5 million patients annually worldwide, yet real-world evidence has remained fragmented and difficult to study across borders. Flatiron’s new offering aggregates structured and unstructured electronic health record (EHR) data from nearly 400,000 patients across Germany, the UK, and the US, all built on a shared common data model to enable seamless cross-market analysis.
The datasets leverage proprietary AI and large language model capabilities to extract and harmonize clinical detail at scale. Researchers gain access to comprehensive Prostate-Specific Membrane Antigen (PSMA) PET scan data, longitudinal prostate-specific antigen (PSA) values, 19 Homologous Recombination Repair (HRR) genes, and detailed recurrence and progression information. The platform is continuously updated to reflect newly approved therapies and shifting treatment paradigms.
“Flatiron is not just adding more data; we are building the singular destination for global oncology intelligence,” said Kate Estep, Chief Product Officer at Flatiron Health. “By unifying fragmented global records into a single evidence platform, we are fundamentally changing how our customers develop therapies and—most importantly—when patients can access them.”
Flatiron says the multiregional design allows life sciences companies to examine variations in diagnostic access, treatment sequencing, and outcomes between health systems—critical as prostate cancer care evolves from early-stage disease through metastatic castration-resistant prostate cancer (mCRPC).
“The field of prostate cancer is evolving at a rapid pace, changing how care is sequenced from early-stage disease through metastatic CRPC and improving outcomes for patients. Yet critical evidence gaps remain, as we see significant regional variation in how novel therapies are used, and in how uneven access to advanced diagnostics differentially influences treatment decisions,” said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. “From a clinical perspective, Flatiron's global Panoramic datasets directly address these evidence gaps, enabling life science companies to increase confidence in decision-making earlier and accelerate development timelines across diseases and geographies, thereby bringing the next generation of precision medicine to all patients sooner.”
Flatiron plans additional global expansions in breast cancer and non-small cell lung cancer datasets in 2027, reinforcing its ambition to define the next standard in AI-driven oncology evidence.
Click here for the original news story.